#1M MaxCyte Driving the Next Generation of Cell-Based Therapies MaxCyte Roadshow Presentation July 2021 CONFIDENTIAL Ⓒ2021 MaxCyte, Inc. All Rights Reserved.#2Disclaimer The content of this document (the "Presentation") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individual or organization to a significant risk of losing all of their investment. If you are in any doubt about the investment to which this Presentation relates, you should consult a person authorized by the Financial Conduct Authority who specializes in advising on securities of the kind described in this Presentation or your stockbroker, bank manager, solicitor, accountant or other financial adviser. This Presentation has been issued by MaxCyte Inc (the "Company") a Company trading on AIM, a market operated by the London Stock Exchange. This does not constitute or form of, not be construed as an offer or invitation to sell or issue or any solicitation of, any offer to purchase or subscribe for any securities in the Company in any jurisdiction. Neither the Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in any connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any such securities. This Presentation does not constitute a recommendation regarding the securities of the Company. This presentation is only addressed to and directed at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (iii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and/or (iv) any other persons to whom this presentation may otherwise lawfully be communicated without contravention of section 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This presentation may not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this presentation relates is available only to relevant persons Certain statements in this Presentation are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "expect", "envisage", "estimate", "intend", "may". "plan", "potentially", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward looking statements, many of which are beyond the control of the Company. In particular, the outcome of clinical trials (including, but not limited to the Company's CARMA trial) may not be favorable or potential milestone payments associated with the Company's licensed programs may not be received. In addition, other factors which could cause actual results to differ materially include risks associated with vulnerability to general economic and business conditions, competition, regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based. No statement in the presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements. July 2021 CONFIDENTIAL M MaxCyte#3Offering Summary Issuer: Exchange / Ticker: Base Offering Size: Over-Allotment Option: Price Range: Lock-Up Provision: Use of Proceeds: Active Bookrunners: Co-Managers: Expected Pricing Date: M MaxCyte July 2021 MaxCyte, Inc. NASDAQ/MXCT (current listing on AIM: MXCT) 12,000,000 shares (100% primary) 1,800,000 shares (100% primary) $11.50 - $13.50 per share 90 days for the Company, directors and officers Various R&D initiatives, including commercialization of the VLX platform (under the ExPERT platform umbrella) Expansion of manufacturing capabilities and investment in manufacturing automation Expansion of sales and marketing, business development and field application scientist teams Working capital and general corporate purposes Cowen, Stifel and William Blair BTIG and Stephens July 29, 2021 (post-market close) · · H CONFIDENTIAL#4A Leading Provider of Cell-engineering Platform With 400+ platforms in place, our proprietary technology platform unlocks the significant potential of advanced therapeutics Leading the growing next- generation cell therapy market and capitalize on rising demand for non-viral engineering approaches • Enables delivery of almost any molecule into almost any cell type • Leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale) • Extensive product portfolio, supported by a robust intellectual property portfolio . -23% 5-year CAGR of organic revenue growth; pharmaceutical-level gross margins of -89% July 2021 20+ years of cell engineering expertise; 20+ field sales and application scientists that support our customers • Significant number of collaborations with industry and academia • Supported by our FDA Master File and International Technical Files to reduce clinical risk/shorten clinical development; referenced in over 30 clinical trials CONFIDENTIAL Innovative business model focused on value creation and shared partnership success • Allows MaxCyte to participate in the value created by our partners' programs • 13 Strategic Platform Licenses (SPLs), which include over $950m in potential pre- commercial milestone payments with upside from commercial sales-based payments • Focused over the long-term on creating a diverse portfolio of patient treatments for indications developed by our strategic partners#5Executive Leadership with Broad Depth of Experience July 2021 Doug Doerfler President and Chief Executive Officer . Co-founded MaxCyte 1998; 20+ years developing MaxCyte's Flow Electroporation® technology Previously CEO of Immunican; various positions at Life Technologies Amanda Murphy, CFA Chief Financial Officer 15 years of equity research experience covering high science tools and diagnostics, cell and gene therapy ecosystem Ron Holtz, CPA Chief Accounting Officer 15 years at MaxCyte; previously public and private company CFO Previous experience in EY's Financial Advisory Services Group Maher Masoud, JD Executive Vice President and General Counsel 21 years as biotech industry attorney and general counsel: Wellstat: Rossi/Masoud LLC; Human Genome Sciences, Inc. Managed legal team/compliance on drug launches negotiated/executed 1,000+ clinical trial agreements, negotiated licensing deals valued at $300+ million Thomas M. Ross Executive Vice President, Global Sales 35+ years of successful sales, marketing and operations leadership in life science and clinical diagnostics markets Previously SVP Commercial Operations at OpGen; Chief Commercial Officer at Predictive BioScience: VP North America Medical Diagnostics Sales at Qiagen/Digene Corporation CONFIDENTIAL Board of Directors J. Stark Thompson, PhD Non-Executive Chairman Doug Doerfler Chief Executive Officer, MaxCyte Yasir Al-Wakeel, BM MCh Non-Executive Director Will Brooke Non-Executive Director M MaxCyte Richard Douglas, PhD Non-Executive Lead Director Stan Erck Non-Executive Director Rekha Hemrajani Non-Executive Director John Johnston Non-Executive Director Art Mandell Non-Executive Director life Luminex MaxCyte KRONOS Harbert Management HMC Corporation genzyme NOVAVAX ONYX EXELIXIS NOMURA seymour CODE pierce Human Genome Sciences#6We Are Just Beginning Our Forward Momentum Impact July 2021 MaxCyte Scalable GT Transfection Scientific System Foundation 1999 Cell Therapy M MaxCyte 2000 FDA Master File 2002 MaxCyte Scalable STX Transfection System VLX Large-Scale Transfection System (prototype) 2005 2008 London Stock Exchange AIM Drug Discovery Listing LSE: AIM March 2016 LON: MXCT 2016 CONFIDENTIAL MaxCyte ATX Gen 2 Transfection System 2018 Processing Assembly Portfolio Expansion MaxCyte EXPERT Platform expert 2019 M MaxCyte 13 Strategic Platform Licenses signed since 2017 65 FTES (19 w/ PhD degrees) 20+ field sales and application scientists* *As of March 31, 2021 2021#7MaxCyte: Leading Partner for Complex Cellular Engineering 50+ Potential SPLs Current addressable market CRISPR July 2021 Allogene 13 SPLS signed since 2017 13 strategic Platform Licenses (SPLs), including 2 signed in 2021- editas APEIRON BIOLOGICS Kite GREAD Beam KSQ® 75+ Programs Clinical Licenses that are part of our SPLs CONFIDENTIAL CARIBOU BIOSCIENCES MYELCID CASEBIA THERAPEUTICS >15% are in the clinic* PRECISION BIOSCIENCES "IND or later CO celularity VOR BIOPHARMA#8Building a Large Portfolio of Diverse Customers MaxCyte's customer base reflects the industry in diversity of cell types, sources, and indications Cell Type/Approach Cell Therapy, Market July 2021 CAR-T Stem Cell MaxCyte Partners TCR Other CAR-NK/NK Cell Therapy Market Cell Source Auto MaxCyte Partners Allo Cell Therapy, Market CONFIDENTIAL MM Note: * All clinical gene modified cell therapies across therapeutic areas (e.g., ancology, inherited disorders, immune disorders) utilizing viral and/or non-viral delivery are included, while other regenerative medicine programs that do not entail genetic modification to obtain a cell-based therapeutic product (e.g.. tissue engineering, immune or stem cell therapies that are not genetically modified) are excluded. Pancreatic Other Solid Tumors Indications MaxCyte Partners AML / ALL Lung Genetic Disorders Other Heme Malig Ovarian NHL Other M MaxCyte#9Continued Investment in Cell Therapy 1,800+ Cell and gene therapies in development globally Source: ASGCT - Pharma Intelligence July 2021 WW Product Sales: US <-700 Genetically-modified cell therapies in development Source: Evaluate Pharma Projected sales of gene-modified cell therapies by 2026 12,000 10,000 8,000 6,000 4,000 2,000 0 (սյա)$ 40+ Allogeneic companies with assets in development Source: William Blair Research 2020 2021 2022 Source: Evaluate Pharma 2023 2024 2025 2026 CONFIDENTIAL Total amount of 2020 global financings for cell and gene therapy companies $19.9B Source: Alliance for Regenerative Medicine First next-generation engineered cell therapy expected to be approved in 2023 2024 Source: Evaluate Pharma#10EXPERTTM Platform Addresses Industry Challenges July 2021 Challenge Development times and cost of viral vectors as delivery method has increased Next-generation cell therapy programs have become increasingly complex Regulatory risk increases with new unknowns (donor cells, 2nd/3rd/4th gen approaches, new indications) Vein-to-vein manufacturing times high; efficiencies needed to deliver medicines to patients faster MaxCyte's Solutions Non-viral approaches address viral vector capacity constraints and safety concerns Flow Electroporation technology facilitates multiplex engineering; challenging with viruses given payload limitations, capacity constraints, and cost FDA Master File can be appended to regulatory filings to reduce regulatory risk EXPERTTM platform provide industry leading efficiency/viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production CONFIDENTIAL M MaxCyte 10#11The EXPERT™ Platform Enabling Non-viral Cell Engineering • Launched in 2019 based on MaxCyte's proprietary Flow Electroporation® technology that has been optimized over 20+ years • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delivers molecules, such as nucleic acids and proteins, to cells • Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology • Enables customers to use a single platform from concept through to the clinic in a GMP environment • Supported by a robust intellectual property portfolio (50+ patents in US and foreign jurisdictions and 75+ patents pending) July 2021 ATX EXPERT Instrument Portfolio Small to mid-scale RUO STx Full scale RUO CONFIDENTIAL GTX High Performance >90% transfection efficiencies (depending on cell type and molecule) >90% cell viabilities Computer-controlled system for reproducible results Scalability - ability to transfect: 75,000 to 7 million cells in seconds Full scale GMP Flexibility • Single, fully-defined, animal component-free electroporation buffer for all cell types Pre-loaded library of validated, cell-specific products Up to 20 billion cells in less than 30 minutes And up to 200 billion cells in less than 30 minutes with the high scale VLX High Quality Sterile, single-use processing assemblies (PAS) - "disposables" Closed, cGMP-compliant, ISO-certified, and CE marked instruments Supported by US FDA Master File and global equivalents 11#12Growing Opportunity from R&D to Therapeutics DRUG DISCOVERY & DEVELOPMENT - CELLS TO DISCOVER DRUGS Blue-chip client base includes the top ten global pharma companies and 20 of the top 25* MaxCyte Revenue Model Instrument sale** Single-use disposables (processing assemblies) Razor/razor blade economics Top pharma by revenue Includes RUO-non-exclusive license only: $119,000 list price for STX sale July 2021 STX ATX J 13 SPLs with cell therapy developers that allow for more than 75 clinical programs; > $950m in potential pre-commercial milestones CELL THERAPY - CELLS AS DRUGS CONFIDENTIAL GT% MaxCyte Revenue Model Annual instrument license fee*** Single-use disposables (processing assemblies) Strategic partnership terms Razor/razor blade economics and share of therapeutic economics *** $150,000 per year lease price for pre-clinical use or $250,000 per year lease price for clinical use 12#13Value Creation from SPLs Licensing deals include significant development milestones and high-value participation in future commercial success of partners Potential value of pre-commercial (clinical development) milestones from SPLs exceeds $950m USD Sales-based payments upon partner's product commercialization July 2021 Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success Milestone revenue is MaxCyte's highest growth tit revenue stream M MaxCyte 2016 CONFIDENTIAL Cumulative Potential Pre-CML Milestones 2017 CASEBIA THERAPEUTICS 2018 CRISPR Beam PRECISION 2019 >$950m USD editas KSQ Kite APEIRON VOR 2020 CO celularity MYELCID CARIBOU BIOSCIENCES Allogene BIOLOGICS 2021#14Example: typical single-product revenues from representative license deal 10 July 2021 0 Commercial Phase Low single digit % share of sales, including sale-based payments, annual instrument fees and disposable sales Approval: Year 5+ Multiple 7-figure milestones. Early Clinical: (Phase 1/2) Years 1-3 Mid-6-figure to Low-7-figure milestones 1-3+ Instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ 7-figure milestone per product Increasing instrument and disposables usage CONFIDENTIAL Cell Therapy Partner Programme Value Schematic Instruments and Processing Assemblies Milestones Sales Based Payments M MaxCyte#152020 2019 2018 2017 2016 2015 Solid 5-year Financial Results 2015-2020 July 2021 Revenue (USD, 000s) 5 Year Revenue CAGR 23% $12,270 $9,290 $16,667 $13,985 $21,620 $26,169 2020 2019 2018 2017 2016 2015 Instruments Placed Rapid Growth of Licensed Placements Gross Margin Pharmaceutical-level Margins ~89% 2015-2020 160 125 + 250+ 200 + 320 + 400 + CONFIDENTIAL Recurring Revenue Average total expected annual revenue from leased instruments and consumabie sales as of 12/31/2015-2020 as % of TTM revenue 2020 2019 2018 2017 2016 2015 Recurring Revenues (% of TTM revenues) 72% Partnered Programs Rapid Growth of Licensed Programs Licensed Clinical Programs M MaxCyte 28% Partnered Programs *Excluding deals signed before 2015 Total Commercial Licenses 12** 8 3 1 0 "3 partnerships signed in 2020 and 1 in early Jan, 2021 15#16Summary and Outlook for 2021+ July 2021 16 ос Prepare / Isolate EB R Culture / Expand 2020 Achievements Wash QC EB R Concentrate Reported 21% revenue growth despite a challenging COVID environment Continued to expand capabilities in engineering new cell types Built our PA portfolio with the introduction of new PAS Expansion of strategic partnerships; 4 in 2020/early 2021; strategic partnership pipeline is the largest it has been Made the decision to re-allocate CARMA™ funding to Life Sciences to accelerate growth 2 3 R 4 Culture CONFIDENTIAL QC R Cryopreserve 1 Strong top-line growth driven by cell therapy Invest in manufacturing expansion/automation Continue to launch new products to address customer needs and expand into new applications Thaw / Dose 2021+ Goals QC Working towards commercializing the large-scale platform (VLx) and associated consumables under the EXPERT brand Future investments in upstream and downstream technologies in cell therapy through partnerships or acquisitions 5 16#17Key Investment Highlights July 2021 Market-leading provider of cell engineering enabling technologies based on proprietary Flow Electroporation® (the EXPERT™ platform) High efficiency, reproducible, scalable non-viral cell engineering system; proprietary platform unlocks potential of engineered cell therapy • Highly recurring revenue enables MaxCyte to realize razor/razor blade economics and capture a part of product economics while delivering high margins (~89% gm across the portfolio) "Go to" non-viral delivery technology critical for manufacturing of next-generation cell therapies Total of 13 SPLs clinical and commercial partnerships; including two strategic license customers added in 2021 • Total potential pre-commercial milestone payments now exceed $950m M Robust full-year 2020 results and strong 2021 revenue growth expected FY20 revenues of $26.2M with year-over-year growth of 21% Strong underlying revenue growth in cell therapy business driven by clinical progression of our existing customers' programs and new customer acquisition due to the most robust SPL pipeline to date Corporate Update • Raised approx. $80M in two transactions principally with top-tier US life science investors Focusing future investment into high-value expansion opportunities to support partners' clinical advancement and commercial launches of therapies enabled by MaxCyte technology CONFIDENTIAL 17#18M MaxCyte Thank you July 2021 Ⓒ2021 MaxCyte, Inc. All Rights Reserved.#19MMaxCyte Appendix#20What is Electroporation? • Electrical pulses are applied to cells suspended between two electrodes, which creates an electric field and polarization of the membrane At a certain electrical field threshold, openings form in the cellular membrane (can be simplistically thought of as pores) • The size and distribution of these openings depends on the intensity of the applied electric field and duration of cell exposure . The openings allow the entry of macromolecules such as RNA, DNA or proteins (such as Cas9/guide RNA complexes) through the cell membrane July 2021 A key discovery in EP was that the e effects of electroporation on the cellular membrane are reversible . Once the electric field is removed, the membrane has the capacity to reseal, trapping the molecules that passed across the membrane within the cytoplasm. 1 3 Cathode (-) RNA CONFIDENTIAL Electrode DNA XX Anode (+) Protein 2 4 Cell Membrane Willk - * 20#21Lentiviral ⠀ Delivering Efficient and Reproducible Gene Transfer While Maintaining High Viability and Function Viral Vectors - Adenovial Retroviral Adeno-Associated Viral High tropism for certain cells/tissue Evolved to efficiently delivery DNA into cells Limited payload capacity; difficult to multiplex July 2021 Concerns around random integration and resulting oncogenesis Expensive to manufacture/ industry-wide capacity constraints EP Competitor A expert™ ↑ ↑ New EP Developers Other non-viral methods Non-Viral Delivery Landscape Clinical Support Scale Performance CGMP ↓ CONFIDENTIAL ↑ " ↓ ✓= ↑ * * * * ↓ ↓ * * Description 20 years of development and optimization; cGMP certified; clinically validated; FDA Master Files and Technical Files Academic and research scale instrument; launched and retracted a 25 ml system a few years ago; not CGMP Academic and research scale and/or bolt-on modules; limited performance data around large- scale EP; not cGMP Numerous other early-stage academic processes/ companies in early-stages of development; limited data around viability/scalability; limited commercial operations#22A Single Delivery Platform for Cell Engineering from Concept to Clinic ATX Concept DOE Optimization Verification Proof of Concept: No large scalability needed ATX primarily used July 2021 GTX Optimization/Verification: ATX or GTX used Option to secure annual research license or purchase the instrument Phase I No clinical/commercial rights or access to-FDA Master File/Technical Files SPL required when the program reaches IND stage. Pivotal CONFIDENTIAL Validation CGMP Production in the Clinic: GTX used SPL required Access to IP and FDA Master File/Technical Files $250k annual license fee per instrument Approval On-Market GTX Approval/ On-Market: SPL required Sales-based payments (royalties in some cases) Access to IP and FDA Master File/Technical Files $250k annual license fee per instrument#23The VLX: Enabling Large Scale Bioprocessing VLX VLX Instrument Specifically designed for extremely large volume cell-engineering July 2021 Capacity to transfect up to 200 billion cells in less than 30 minutes - 10 times the capacity of the GTX In beta testing for large scale bioprocessing applications Key Applications 3 · Up to 200 billion cells VLx in < 30 minutes Future Recombinant proteins Viral vector · · expert™ VLx Instrument Working towards launching the VLX under the EXPERTTM brand CONFIDENTIAL Ease-of-use and cell handling improvements cGMP compliance GMP consumables Virus-like particles (VLPs) Allogeneic cell therapies Vaccines#24MaxCyte's IP and Protection Fundamentals July 2021 FDA Master File Application IP Platform IP Instrument and Design IP CONFIDENTIAL Know- How 50+ patents in US and foreign jurisdictions (including Australia, Canada, Japan, China, South Korea, and certain European countries) • 76+ pending patent applications worldwide M MaxCyte 24#25FDA Master File Helps Customers Efficiently Navigate Path to the Clinic Established in 2002, MaxCyte Master File/Technical Files now referenced in over 30 clinical trials Current countries: • US, Canada, Japan; and UK and Austria Discussions underway with additional regulatory authorities: Australia, Germany, Thailand and China Allows MaxCyte to issue a letter of authorization (LOA) to cell therapy partners for clinical trials in US and countries listed above LOA allows partners to instantly reference all the information in the Master File as part of their own cell therapy product submission to regulatory authorities July 2021 Information in the Master File remains confidential File has been updated with every substantial change to EP systems CONFIDENTIAL M MaxCyte#26-40% of Clinical Programs Utilizing Non-Viral Delivery Already Captured; More Discussions Ongoing Diversified Supplier Therapeutic Developers Source: Company Estimates *Percentages are approximate and sum to greater than 100% July 2021 Non-Viral Delivery Competitor Share - Clinical Programs, U.S. Only 10% 20% n=~40 Non-Viral Delivery Clinical Programs (Estimated*) 20% 40% MaxCyte MaxCyte (in discussions) Therapeutic Developers 15% Pure-play Cell Engineering M MaxCyte Delivery Technology Undisclosed Diversified Supplier CONFIDENTIAL Non-viral delivery adoption is driven by: Nuclease mediated gene editing Complex engineering, next-generation approaches High cost and complexities of viral vector manufacturing M MaxCyte 26#27Proprietary Flow Electroporation Technology for Cell Engineering July 2021 Any Cell Any Molecule Primary cells Stem Cells (iPSCS) Insect cell lines lon channels GPCRs Transporters Receptors CRISPR/CAS9 . • Immortalized mammalian cell lines Mammalian cancer cell lines Hematopoietic cells TALENS siRNAS/ASOs Nucleases Enzyme reporters • Transcription factors Epigenetic regulators . Antibodies Lentivirus/AAV Bi-specifics Alphavirus Adenovirus VLPS Subunit vaccines Fusion proteins Antigens CONFIDENTIAL APPLICATIONS OF ENGINEERED CELLS GO 国 Cell therapy Transient protein production Vaccines and viral vectors Stable expression Small molecule discovery M MaxCyte 27#28Cell Therapy Market is Expected to Double Over Next 5 Years across All Approaches and Segments Projected Number of Genetically-modified Cell Therapy Programs (2020-26) Number of Programs July 2021 1,600 1,400 1,200 1,000 800 600 400 200 0 Currently 4 approved therapies -670 2020 ~1,000 2023 Preclinical Clinical Commercial ~1,400 Consistent, substantial market growth, including in the non-viral delivery segment, is expected to increase MaxCyte's addressable opportunity overall Source: DeciBio Cell Therapy Model, Interview Feedback CONFIDENTIAL 2026 13% CAGR 2020-2026 ******* >50 Approved therapies by 2026 …………………………‒‒‒‒‒‒‒‒‒‒‒‒‒‒ >10 Distinct approved indications by 2026 M MaxCyte 28#29MMaxCyte Case Studies#30Significant Increase in Both Efficiency and Viability Over Competing Technologies A study completed at a leading academic institution in Japan showed improved knock-in (KI) efficiency and higher cell viability compared to a competing electroporation platform for the correction in induced pluripotent stem cells (iPSC). E Knock-in (Pstl) [%] sSODN [pg] July 2021 Customer generated data showed higher editing efficiency S691C (Pstl) knock-in efficiency 13 4D-Nucleofestor 0 MaxCyte F Knock-in (EstUI) [%] 10 G694A (BstUI) knock-in efficiency 0 SSODN [ug] 0 6.7 13 4D-Nucleofector 0 MaxCyte Relative cell number [%] CONFIDENTIAL 120 100 RNP SSODN Electroporation Higher cell viability compared to competing technology الأمم المال Source: Kagita et al, Efficient sSODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports ISSCR. April 2021. 6.7 13.3 67 133 4D-Nucleofector + 6.7 13.3 6.7 13.3 MaxCyte M MaxCyte#31High Cell Viability and Transfection Efficiency across a Variety of Cell Types Ten different cell types were transfected with PGFP DNA using pre- loaded protocols on the MaxCyte STX platform. The results showed that cell viability and transfection efficiency exceeded 90 % across all cell types using MaxCyte's STx platform. CHO 90% Viable 90% GFP Hola 92% Viable 90% GFP Huh-7 90% Viable 80% GFP K562 90% Viable 90% GFP- Vero 90% Viable 90% GFP Renca 97% Viable 80% GFP July 2021 NIH 3T3 90% Viable 90% GFP Primary Fibroblasts 95% Viable 96% GFP hMSCs 80% Viable 80% GFP HEK 293 95% Viable 96% GFP Figure 1: The MaxCyte STX comes preloaded with optimized electroporation protocols for a variety of cell types. Ten different cell types were transfected with 2 µg/1E6 cells of PGFP DNA using the appropriate MaxCyte STX protocol. 24 hours post transfection cells were examined for cell viability (% cells excluding propidium iodide, Pl) and transfection efficiency (% cells GFP). High viability and efficiency across many cell types A study published in Nature Immunology from a leading US academic institution examined the CRISPR-Cas9-mediated gene knockdown of murine primary T cells using CRISPR ribonucleoproteins (RNPs). The study demonstrated RNP transfection efficiencies were consistently greater than 90% using MaxCyte's ATX platform. Quantification of cell viability and transfection efficiency of RNP and RNP CONFIDENTIAL b SSC FSC 08/peagwNT CD4-8V510 4 ATTO-550 RNP RNP Cell Viability Live CD4 (%) Electroporation Efficiency RNP* (%) RNP transfection efficiencies were consistently greater than 90% and >85% cell viability with MaxCyte ATX Customer generated data showed high viability and efficiency in T-cells 31#32Seamless Scale-up from 100ul to 1,000ul Transfection Volume with No Loss of Editing Efficiency in Primary T Cells A study conducted at a leading US academic institution evaluated gene-editing efficiency in primary CD45+/CD3- T cells using MaxCyte's ExPERT Platform at 100uL and 1,000uL volumes. After 5 days following electroporation, the data showed ~95% editing with no change in efficiency despite a 10x difference in scale. Feature Cassette type Max volume Min volume # EP/cassette Low cell # High cell # July 2021 OC-100 M 100UL 50uL 1 500,000 20 million R-1000 U 1mL 500uL 1 5 million 200 million % CD45+/CD3- 100 80 60 40 20 0 CONFIDENTIAL High editing efficiency across PAS (10x difference in scale) and lasting 79% 80% 48 Hours ■No EP ■OC100 R1000 95% Day 5 96% M MaxCyte#33Ability to Drive Complex Engineering Via Non-Viral Delivery for CRISPR-Engineered T Cells in Patients with Refractory Cancer A human phase 1 clinical trial was conducted at a leading US academic institution to assess the safety and efficacy of a multiplexed TCR T Cell Therapy using CRISPR ribonucleoproteins (RNPS) targeting TRAC, TRBC and PD-1 and transduced NY-ESO-1 TCR cells. The delivery of CRISPR RNPS targeting the three genes was enabled by the MaxCyte EXPERT Platform. The results showed 90% on-target editing efficiency of CRISPR RNPs targeting TRAC, TRBC and PD-1. July 2021 MaxCyte Gene Editing in an Efficient T Cell Manufacturing Workflow Leukapheresis | T Cell & Elutriation Day Activation 3 5 TRAC, TRBC & PD-1 RNP Electroporation 6 Expansion 10 TCR Transduction NY-ESO-1 TCR 16 Lentiviral Vector Rx Harvest, Formulation & Cryopreservation Customer generated data showed multiplex editing CONFIDENTIAL Table 1: Measurement of On-Target Editing Efficiency for Each Gene by Final Product On-Target Editing Efficiency (%) TRAC TRBC 96.1 96.8 97.0 Manufactured NYCE T Cell Product (subject ID) UPN07 UPN27 UPN35 UPN39 Average ± SD PDCD1 100.0 99.6 99.8 98.2 99.4 ± 0.8 99.6 99.1 99.1 96.7 98.6 ± 1.3 93.5 95.8 ± 1.6 33#34Reduction in CAR-NK Manufacturing Times Compared to Viral Vectors Preclinical anti-CD19 NK-CAR cells were developed using MaxCyte's GTX system (electroporated mRNA encoding anti-CD19 CAR) and retroviral transduction (anti-CD19-BB-7 construct) methods separately. The results showed transfection efficiency was higher with MaxCyte's GT platform (87% +/- 6%) relative to retroviral transduction (60% +/- 20%) . MaxCyte's GTX system saved roughly 10 days in manufacturing time compared to viral vectors given the more rapid transfection process and fewer days of culture time required. July 2021 ††† ↑ Healthy Donors Expanded NK Cells Expanded NK Cells Retroviral Infection on 2 Consecutive Days -2 Days Anti-CD19 CAR <1 Hour - 24 Hours mRNA Encoding Anti-CD19 CAR with MaxCyte GT 87% + 6 Transfection Efficiency CONFIDENTIAL 8-10 Days Anti-CD19 CAR Customer generated data showed manufacturing time reduction versus viral approaches 60% + 20 Transduction Rate M MaxCyte 34